TransCode Therapeutics Postpones Special Meeting
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), dedicated to advancing cancer treatment through RNA therapeutics, has announced an important update regarding its Special Meeting. Initially scheduled for a recent date, the meeting has been adjourned until a later date to allow for more stockholder participation and secure the necessary votes on critical company proposals.
Understanding the Reason for the Adjournment
The decision to postpone the meeting was made due to insufficient stockholder representation required to achieve a quorum for the voting process. At the recent meeting, only about 29.94% of the shares entitled to vote were represented. A quorum, defined as at least one-third of the outstanding shares, is necessary for the meeting to proceed effectively. The new date for the Adjourned Special Meeting is set for February 25 at 9:30 a.m. (Eastern Time), with a focus on enhancing participation.
Key Proposals Under Review
During this upcoming meeting, stockholders will be asked to vote on two significant proposals. The first proposal is concerned with compliance under Nasdaq Listing Rule 5635(d), which involves the full issuance of shares of Common Stock upon the exercise of specific warrants (Series C and D Warrants). This entails several adjustments to the exercise price and features of the warrants to ensure proper alignment with market expectations.
The second proposal suggests the possibility of adjourning the meeting again if necessary to permit further solicitation of votes on the first proposal. This approach illustrates TransCode's commitment to ensuring all stockholders have the opportunity to contribute their voice to these pivotal decisions.
Participation in the Adjourned Special Meeting
The Adjourned Special Meeting will take place virtually. Stockholders are encouraged to participate by visiting the designated meeting website where they can listen in, vote, and submit questions during the live event. This virtual format aims to offer greater accessibility and engagement for all eligible stockholders wishing to contribute to the decisions affecting TransCode's future.
Voting Process for Stockholders
For stockholders who wish to vote on the proposals, there are multiple options available. Voting can be facilitated by using a proxy card sent out by the company, ensuring that stockholders can express their preferences directly. It's crucial to submit your votes prior to the deadline to ensure they are counted during the Adjourned Special Meeting.
Why Your Vote Matters
TransCode values the input of its stockholders and aims to ensure that decisions made reflect the interests of those invested in the company. Each vote plays a critical role in shaping the direction of TransCode's approach to cancer treatment and the implementation of its innovative RNA therapeutic strategies.
About TransCode Therapeutics
As a clinical-stage oncology company, TransCode is committed to providing effective treatment options for metastatic diseases. Its innovative TTX nanoparticle platform is designed to enhance the delivery of RNA therapeutics, particularly its lead candidate, TTX-MC138, which targets tumors associated with specific biomarkers. This dedication to research and development showcases TransCode's proactive approach in addressing the complexities of cancer therapeutics.
Frequently Asked Questions
What is TransCode Therapeutics?
TransCode Therapeutics, Inc. is an RNA oncology company specializing in innovative treatments for cancer through RNA therapeutics and drug delivery systems.
Why was the Special Meeting adjourned?
The Special Meeting was adjourned due to insufficient stockholder representation, as a quorum was not reached to proceed with voting on key proposals.
When is the rescheduled meeting?
The Adjourned Special Meeting is scheduled for February 25 at 9:30 a.m. Eastern Time.
How can stockholders vote?
Stockholders can vote via proxy card, during the virtual meeting, or through online platforms identified by the company. It is important to vote by the deadline to ensure your vote is counted.
What proposals will be voted on?
Stockholders will vote on the Issuance Proposal regarding the Common Stock from warrants and an Adjournment Proposal if further solicitation for votes is necessary.
